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Recent studies have focused their attention on the role of the proinflammatory cytokine tumor
necrosis factor (TNF) in the development of heart failure. First recognized as an endotoxin-
induced serum factor that caused necrosis of tumors and cachexia, it is now recognized that
TNF participates in the pathophysiology of a group of inflammatory diseases including
rheumatoid arthritis and Crohn’s disease. The normal heart does not express TNF; however,
the failing heart produces robust quantities. Furthermore, there is a direct relationship
between the level of TNF expression and the severity of disease. In addition, both in vivo and
in vitro studies demonstrate that TNF effects cellular and biochemical changes that mirror
those seen in patients with congestive heart failure. Furthermore, in animal models, the
development of the heart failure phenotype can be abrogated at least in part by anticytokine
therapy. Based on information from experimental studies, investigators are now evaluating the
clinical efficacy of novel anticytokine and anti-TNF strategies in patients with heart failure;
one such strategy is the use of a recombinantly produced chimeric TNF alpha soluble
receptor. Thus, in view of the emerging importance of proinflammatory cytokines in the
pathogenesis of heart disease, we review the biology of TNF, its role in inflammatory diseases,
the effects of TNF on the physiology of the heart and the development of clinical strategies
that target the cytokine pathways. (J Am Coll Cardiol 2000;35:537–44) © 2000 by the
American College of Cardiology
Dilated cardiomyopathy is a disease of epidemic proportion
in the U.S. Although more prevalent in the elderly, it affects
patients of all ages, races and genders. Heart failure is
generally believed to begin with myocyte damage secondary
to a variety of insults including ischemia, toxins such as
alcohol or immune mechanisms. However, in many cases
the etiology remains undefined. Initially the heart compen-
sates by dilatation and cellular hypertrophy; however, over a
period of time, the heart eventually decompensates and
patients present with signs and symptoms of heart failure. It
is the transition from compensation to decompensation that
has been the focus of clinical and basic research over the past
two decades and the role of the neurohormones, norepi-
nephrine and angiotensin II, in the development of symp-
tomatic heart failure. However, investigators have recently
focused their attention on the proinflammatory cytokine,
tumor necrosis factor (TNF). This manuscript reviews the
investigational data supporting the role of TNF in the
pathogenesis of heart failure and its usefulness as a thera-
peutic target.
The proinflammatory cytokine TNF. In 1975, Carswell
et al. (1) first identified tumor necrosis factor (TNF), an
endotoxin-induced serum factor that caused necrosis of
tumors. A decade later, investigators isolated a protein from
endotoxin-treated cells that was named cachectin because of
its presumed role in the molecular basis of cachexia (2,3).
The subsequent cloning of the genes encoding cachectin
and TNF alpha confirmed that these two molecules were
identical (4,5). Produced as a prohormone of 233 amino
acids, TNF alpha is anchored in the cell membrane and then
processed to a 157 residue mature protein by cleavage of a
76 residue signal peptide. In response to a wide variety of
infectious or inflammatory stimuli (e.g., lipopolysaccharide,
viruses, fungal or parasitic antigens, interleukin-1 [IL-1],
TNF alpha), both transcription and translation of TNF
precursor is increased, and large amounts of mature protein
are rapidly released into the circulation. However, not all of
the TNF alpha is released as some remains cell-associated in
a transmembrane form (6). Tumor necrosis factor regulates
the expression of a variety of peptide regulatory factors
including IL-1, IL-6, platelet derived growth factor, trans-
forming growth factor-beta, as well as a group of eico-
sanoids and hormones including platelet-activating factor
and adrenaline (7). In addition, TNF alpha (and IL-1beta)
contains a 33 nucleotide 39-untranslated sequence that
shortens messenger RNA (mRNA) half-life and, in so
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doing, limits the production of large quantities of this
potent peptide (4).
TNF receptors. Once released from the cell, TNF alpha
interacts with one of two TNF alpha receptors—a 55 kd
high affinity receptor, soluble tumor necrosis factor receptor
1 (TNFR-1), and a 75 kd low affinity receptor (TNFR-2)
(8,9). Intracellular signaling occurs as a result of TNF
alpha-induced cross-linking of the receptors. The extracel-
lular portions of these two proteins form a receptor family
containing four characteristic domains with regularly spaced
cystine residues; however, no significant homology exists
between the intracytoplasmic portions of the two TNF
alpha receptors (10). Thus, investigators have proposed that
these receptors may be coupled to distinct signaling path-
ways (11). In the presence of noxious stimulants including
TNF alpha, lipopolysaccharide (LPS), okadaic acid and
phorbol esters, TNF alpha receptors are “shed” into the
circulation (12–14). These TNFR receptor proteins appear
to be truncated fragments of the extracellular regions of the
type 1 and type 2 membrane-bound receptors for TNF
alpha (13,15). Although TNF receptors do not possess
intrinsic protein kinase activity, within minutes of exposure
to TNF alpha, phosphorylation of several distinct proteins
occurs, which is likely due to activation of cellular kinases
(16). The soluble receptors are able to bind ligand and
inhibit the cytotoxic activities of TNF alpha (15). Thus, the
shedding of soluble binding proteins might serve as a
“biological buffer” that can rapidly neutralize the activities of
TNF alpha.
Pleiotropic effects of TNF alpha. The cellular effects of
TNF alpha are highly pleiotropic. At low concentrations,
TNF alpha effects paracrine or autocrine regulation of
leukocytes and endothelial cells and, thus, serves as an
important regulator of the inflammatory response. Indeed,
mice lacking the p55 TNF alpha receptor are highly
sensitive to some types of bacterial infections (17). Tumor
necrosis factor alpha enhances chemotaxis of macrophages
and neutrophils, increases their phagocytic and cytotoxic
activity (18) and promotes leucostasis by inducing increased
expression of intracellular adhesion molecules (ICAMS)
and endothelial leukocyte adhesion molecules (ELAMS) at
sites of inflammation. At higher concentrations, TNF alpha
production exceeds the number of TNF alpha receptors
located on the cell surface with excess TNF alpha being
released into the circulation. Once released, TNF alpha
exerts endocrine or exocrine effects including initiation of
metabolic wasting, microvascular coagulation, hypotension
and fever (19,20). Paradoxically, TNF alpha also appears to
modulate both tissue destruction and rebuilding. Tumor
necrosis factor alpha stimulates fibroblast and mesenchymal
cell proliferation directly and induces the biosynthesis of
other growth factors. By contrast, it is directly cytotoxic to
endothelial cells and can induce the biosynthesis of collag-
enases, proteases, reactive oxygen intermediates and arachi-
donic acid metabolites (7). Tumor necrosis factor alpha has
also been shown to have an important role in cell death
through a variety of mechanisms including second messen-
ger pathways, arachidonate metabolism, protein kinases,
oxygen free radicals, nitric oxide, transcription of a variety of
cytotoxic genes, regulation of nuclear regulatory factors,
ADP-ribosylation and, potentially, DNA fragmentation
(21). Under normal situations, these cytotoxic effects are
important in host defense by initiating antitumor activity
(1,22) and modulating cell growth and differentiation.
However, the role of TNF alpha in the pathogenesis of
malignancies remains controversial. While therapy with
TNF improved survival in tumor-bearing mice, it also
promoted tumor cell adhesion, nodule development (23)
and metastasis (24). In addition, a direct relationship exists
between the level of TNF expression and tumor grade in
ovarian cancer (25). By contrast, excessive activation of
TNF alpha or nontissue specific expression leads to tissue
necrosis and apoptosis. Indeed, recent studies have demon-
strated a causative role for TNF alpha in a group of diseases
including: septic shock, rheumatoid arthritis (26), pre-
eclampsia (27), hemolytic uremic syndrome (28), allograft
rejection (29) and regional enteritis (30).
Proinflammatory cytokines and the heart. The first rec-
ognition that TNF alpha might participate in the develop-
ment of congestive heart failure (CHF) came in 1990 when
Levine et al. (31) demonstrated that circulating levels of
TNF alpha were elevated in patients with end stage heart
failure and cachexia. Subsequent studies demonstrated com-
parable elevations in IL-6 and IL-1beta (32) and a direct
relationship between TNF alpha levels and functional heart
failure classification (Fig. 1 [33]). Furthermore, direct rela-
tionships were identified between circulating levels of TNF
alpha and neurohumoral activation and the degree of
anemia; however, there was no relationship between cyto-
kine levels and the degree of cachexia (34,35). Cytokine
levels were also elevated in patients with heart failure due to
myocarditis (36). That the observed increases were of
physiologic significance was demonstrated by studies in
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which injections of endotoxin into humans resulted in TNF
alpha elevations, depressed left ventricular function and
decreases in mean arterial pressure (37). Parenthetically, it
should be noted that the different assay techniques, for
example bioassays or ELISA measurements, used by various
investigators provide varying values, thus obfuscating the
literature to some extent.
The increase in circulating TNF alpha in patients with
CHF was associated with a substantial decrease in
myocardial TNF alpha receptors and an increase in soluble
TNF alpha receptors; however, the stoichiometry favored
free TNF alpha (38). Perhaps of greatest importance was
the demonstration by Mann and colleagues (38) in 1996
that the nonfailing human heart does not express TNF
alpha, whereas the end stage failing human heart reexpresses
robust amounts of protein (Fig. 2).
Biologic effects of TNF alpha on the myocardium.
Beginning with the observation that TNF alpha could
inhibit contractility of isolated hamster papillary muscles in
a concentration-dependent and reversible manner (39), a
series of in vivo and in vitro basic science studies were
performed, which paralleled the clinical studies assessing
TNF alpha levels in patients with CHF (Fig. 3). First, it was
demonstrated that the negative inotropic effects of
TNF alpha are virtually immediate (40,41) and appear to be
completely reversible upon removal of the cytokine. How-
ever, not only does TNF alpha have immediate negative
inotropic properties, but it can recapitulate the cellular and
biochemical abnormalities that characterize the failing hu-
man heart. For example, IL-1beta induces a down regula-
tion of the expression of sarcoplasmic reticulum Ca21
ATPase (SERCA) and phospholamban at both the mRNA
and protein level in neonatal myocytes (42), which is
associated with a depression and prolongation of the Ca21
transient, effects that may be initiated by TNF alpha (40). In
addition, TNF alpha effectively uncouples the beta-
adrenergic receptors from adenylyl cyclase via an effect on
the G inhibitory protein (43,44). Furthermore, TNF alpha
activates metalloproteinases and inhibits the expression of
inhibitors of metalloproteinases in vivo—effects that would
be expected to activate extracellular matrix remodeling (45).
Although initial studies suggested that the negative inotrop-
ic properties of TNF alpha were attributable to the ability of
cytokines to induce nitric oxide synthase, subsequent inves-
tigations demonstrated that the induction of inducible nitric
oxide synthase could not in and of itself induce contractile
dysfunction in cardiac myocytes and that alterations in
calcium homeostasis played an important role (40). Tumor
necrosis factor alpha also provokes a hypertrophic growth
response in cardiac myocytes, which may be an adaptive
response to hemodynamic or environmental stress (46).
Furthermore, a recent study suggested that the immediate
negative inotropic effects of TNF alpha may be mediated by
Figure 1. Circulating levels of tumor necrosis factor alpha (TNF
alpha) in normal subjects and patients with New York Heart
Association (NYHA) functional class I to III heart failure.
Adapted after Torre-Amione et al. (33) with permission of the
authors.
Figure 2. Immunodetectable TNF alpha (picograms of TNF alpha
per g of cystolic protein) in nonfailing and failing myocardium.
Adapted after Torre-Amione et al. (38) with permission of the
authors.
Figure 3. Tumor necrosis factor alpha acutely depresses contractile
activity and calcium transients of isolated adult rat cardiomyocytes.
Cells were loaded with the calcium sensitive dye, fura-2, and
exposed to 200 U/ml rat TNF alpha or diluent (control) for
30 min. Cells were then electrically stimulated to contract (1 HZ)
and a video edge-detection system used to record diastolic cell
length and contraction to determine fractional shortening. Cells
were alternately illuminated at 340- and 380-nm light and emis-
sion of the fura-2 measured at 520-nm. The ratio of light emission
from the two illuminating wavelengths was used to follow intra-
cellular free calcium transients. (A) Fractional shortening (n 5 30
each group). (B) Mean calcium transient amplitude (difference
between peak systolic and peak diastolic 340/380 nm ratio; n 5 40
per group). (Wagner, Combes, Janczewski, McTiernan and Feld-
man; unpublished data). Open square 5 control; solid square 5
TNF alpha 200 U/ml.
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sphingosine (47). Finally, chronic infusion of TNF alpha
produces a reversible dilated cardiomyopathy in a rat mod-
el—without evidence of inflammatory infiltrate or myocyte
necrosis (48).
TNF alpha transgenic mice—a model of dilated cardio-
myopathy. To pursue further studies of the role of cyto-
kines in the development of CHF and to provide additional
support for the “cytokine hypothesis,” a series of mice that
harbored a transgene effecting cardiac-specific overexpres-
sion of TNF alpha were generated using the cardiac-specific
alpha myosin heavy chain (alpha-MHC) promoter. Robust
overexpression proved lethal due to (49) fulminant myocar-
ditis; however, lower levels of TNF alpha expression allowed
the production of viable founders (50). These mice recapit-
ulate heart failure in humans as they demonstrate: 1)
four-chamber dilatation, 2) myocyte hypertrophy, 3) inter-
stitial infiltrates, 4) extracellular matrix remodeling with
fibrosis, 5) diminished beta-adrenergic responsiveness; and
6) premature death with a six-month mortality of 25% (Fig.
4). The development of a heart failure phenotype secondary
to overexpression of TNF alpha has recently been confirmed
by a second laboratory (51). Taken together, the existing
TNF alpha transgenic studies suggest that there is a direct
relationship between transgene copy number and the degree
of inflammation (52). Recent studies suggest that mortality
in these animals is due, in part, to an arrhythmogenic event
since continuous holter monitoring of transgenic mice
demonstrates high grade ventricular ectopy with frequent
runs of nonsustained ventricular tachycardia (53). At the
cellular and molecular level, the TNF alpha transgenics are
characterized by: 1) reexpression of the fetal gene program
(e.g., atrial natriuretic factor and beta-MHC), 2) reexpres-
sion of downstream TNF alpha responsive cytokines and
chemokines including IL-1beta, monocyte chemoattractant
protein (MCP), and regulated upon activation, normal
T-cell expressed and secreted, 3) increased activity of the
metalloproteinases and diminished expression of inhibitors
of metalloproteinases (54), 4) activation of both pro- and
antiapoptotic pathways (55), 5) down-regulation of phos-
pholamban and SERCA expression, and 6) a decrease in the
alpha- and beta-myosin heavy chain mRNA ratio (56,57).
Furthermore, the transgenic mice demonstrated reduced
ejection fractions and fractional shortening and diminished
ventricular compliance. The TNF alpha transgenic also
demonstrated a substantial amount of apoptosis; however,
this was largely isolated to the interstitium, and myocyte
apoptosis was rare (55). Thus, the TNF alpha overexpress-
ing transgenic recapitulates both the pathologic, cellular and
molecular phenotype of the human failing heart and, there-
fore, provides an ideal model in which to study the patho-
biology of progressive CHF and to test therapeutic strate-
gies.
“Rescuing” the TNF alpha transgenic with TNFR. That
there was a direct relationship between TNF alpha expres-
sion and negative inotropic effects was first shown by
Kapadia et al. (58) using soluble TNF alpha binding
proteins. However, to “prove” that overexpression of TNF
alpha is a critical step in the development of end stage CHF
(52), transgenic and wild type mice were injected with an
adenoviral vector encoding a chimeric soluble TNF alpha
protein consisting of two moieties of the human 55-kDa
TNF alpha receptor extracellular domain fused to a mouse
IgG heavy chain (59). Inoculation of mice with 109 plaques
forming units resulted in inhibitor production and release by
hepatocytes and marked elevations in serum and myocardial
TNF alpha receptor levels for as long as six weeks (57).
These levels of soluble receptor were several orders of
magnitude greater than the levels of myocardial TNF alpha,
suggesting a favorable stoichiometry for TNF alpha inhibi-
tion. After both two and six weeks of treatment, TNFR
completely abrogated the presence of interstitial infiltrates
and normalized the expression of alpha-MHC, SERCA,
and phospholamban. In addition, the reexpression of down-
stream cytokines and chemokines including IL-1beta,
MCP-1 and rantes was completely inhibited by TNFR
Figure 4. Transgenic mice with cardiac-specific overexpression of
TNF alpha (TNF1.6) develop dilated cardiomyopathy. Represen-
tative magnetic resonance image (MRI, coronal view) from 24
week-old wild type (A) and TNF1.6 transgenic mice (B) at
equivalent stage of cardiac cycle. (C) Transgenic animals demon-
strate significant cardiac hypertrophy with chamber dilation and
decreased ejection fraction as determined from MRI data (short-
axis images). Adapted after Kubota et al. (50) with author’s
permission. BW 5 body weight; EDV 5 end-diastolic volume;
ESV 5 end-systolic volume; HW 5 heart weight. Open
square 5 wild type; solid square 5 TNF1.6. *p , 0.05.
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therapy. By contrast, there was continued activation of
beta-MHC expression, which was consistent with the
finding of persistent ventricular hypertrophy in these TNFR
treated mice. Finally, there was normalization of matrix
metalloproteinase and tissue inhibitor of metalloproteinase
expression and stabilization of the degree of interstitial
fibrosis, suggesting that extracellular matrix remodeling had
abated. Thus, these studies suggest that some, although not
all, of the phenotypic characteristics of CHF can be abated
by anticytokine strategies. However, both hypertrophy and
fibrosis persist despite therapeutic intervention, suggesting
early, but not late, therapy using anticytokine approaches
might benefit patients with CHF.
The molecular genetics of TNF alpha. Genetic polymor-
phisms in the TNF locus have been associated with higher
levels of TNF alpha production (60,61) and are known to be
related to several autoimmune, infectious and neoplastic
diseases (62,63). These polymorphisms include a G to A
transition at position 2308 in the promoter region of the
TNF alpha gene (TNF alpha2) (64) and a G to A transition
at position 1252 in the first intron of the TNFbeta gene
(65). The frequency of the TNF alpha2 allele, the allele
associated with increased TNF expression, is increased in
patients with rheumatoid arthritis and systemic lupus ery-
thematosus (66). Similarly, people homozygous for the
TNF alpha2 allele have a higher risk for death due to
cerebral malaria (67) while homozygous for the TNFbeta2
allele have a higher mortality with sepsis (61). To date,
investigators have been unable to demonstrate an associa-
tion between either the TNF alpha or TNFbeta polymor-
phisms and the presence of CHF (68); however, these
studies had an inherent bias, i.e., that patients with a
potentially unfavorable polymorphism might have died prior
to receiving medical attention (69). Therefore, further
evaluation of this possibility is warranted. An additionally
important, but as yet unanswered, question is how myocar-
dial TNF alpha expression is regulated at the molecular
level. However, interactions of nuclear proteins with an
Ap-1/CRE-like (cis-acting regulatory site) promoter se-
quence in the human TNF alpha gene (70) and the marked
sensitivity of TNF alpha expression to corticosteroids (and
possibly cyclic adenosine monophosphate [AMP]) suggest
the importance of transcriptional regulation in modifying
TNF alpha expression (71–73).
Clinical strategies for anticytokine therapy. Based on the
basic science and clinical observations regarding the role of
proinflammatory cytokines in the development of CHF,
efforts have been directed towards developing anticytokine
strategies that might be useful in the therapy of patients.
Yoshimura et al. (74) suggested that beta-adrenergic ago-
nists could inhibit the production of both TNF alpha and
IL-1beta by elevating intracellular cyclic AMP levels. Sim-
ilarly, pretreatment with isoproterenol blunted the ability of
LPS to induce TNF alpha production in conscious mice
(75), whereas short-term, but not long-term preexposure of
mononuclear cells to adrenergic agonists inhibited LPS-
induced production of TNF alpha (76). Phosphodiesterase
inhibitors can also serve as potent inhibitors to TNF alpha
production (77,78). Indeed, the phosphodiesterase inhibi-
tor, pentoxyfilline, demonstrates salutorius effects on heart
failure signs and symptoms while substantially lowering
circulating TNF alpha levels (79,80). However, other stud-
ies have failed to show an effect of cyclic AMP, cyclic AMP
derivatives or beta-adrenergic agonists on TNF alpha pro-
duction (81). Other inhibitors of cytokine expression in-
clude: amiodarone (82), ouabain (83) and thalidomide (84).
In addition, a recent report suggests that estrogen may
constitutively down-regulate TNF alpha expression (85).
Recently, studies have demonstrated that adenosine is a
potent inhibitor of TNF alpha expression by both neonatal
myocytes, adult myocytes, rodent papillary muscle prepara-
tions and adult human heart via activation of the adenosine
A2 receptor (86,87). This effect appears to be partially
selective for the heart as adenosine’s anticytokine effects in
white cells is mediated via the A3 adenosine receptor (88).
That adenosine may have an important role in regulating
myocardial cytokine expression was further supported by a
recent study by Loh et al. (89) demonstrating improved
survival in heart failure patients having a common mutation
in at least one allele of the AMP deaminase gene. In the
peripheral muscle, and presumably in the heart, patients
with this mutation have diminished AMP deaminase activ-
ity resulting in decreased metabolism of AMP to inosine
and enhanced production of adenosine, leading us to hy-
pothesize that adenosine agonists might have therapeutic
utility in the management of patients with CHF (69).
Effective blockade of TNF alpha activity has also been
effected using passive immunization. Monoclonal antibodies
against TNF alpha have proved successful in ameliorating
the effects of sepsis (in animal models) (90,91), cancer (92),
synovial inflammation (93), inflammatory bowel disease
(94,95) and chronic bacterial infection (96,97). While im-
munotherapy is effective for investigation studies in animal
models, it has limitations in long-term disease therapy as
the antibodies serve as immunogens and, therefore, can only
be used for a limited period of time. To abrogate the
immunogenicity of the antibody, several groups have pro-
posed using monoclonal antibodies in combination with an
immunosuppressive such as methotrexate. However, the
rationale for using a potent immunosuppressive in a patient
with a chronic disease such as heart failure remains ques-
tionable.
Perhaps the most exciting strategy that has recently been
developed for inhibiting the effects of myocardial TNF
alpha production is the use of a recombinantly produced
chimeric TNF alpha soluble receptor (Etanercept; Immu-
nex, Seattle, Washington) consisting of the p75 receptor
linked to the Fc portion of human IgG (TNFR:Fc). Unlike
synthetic pharmacologic agents that can have multiple
cellular effects, recombinant proteins have the theoretical
benefit of being highly specific. First used in the treatment
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of rheumatoid arthritis, Etanercept was associated with
dose-related reductions in disease activity without dose-
limiting toxicity or the development of antibodies to the
recombinant receptor protein (98). Based on the salutorious
effects of Etanercept in clinical trials of patients with
rheumatoid arthritis, the agent was recently approved by the
Food and Drug Administration. However, postmarketing
surveillance has raised cautions regarding the use of the
agent in patients with serious infections.
In a Phase I study assessing the safety of soluble TNF alpha
receptor therapy in patients with CHF, a single intravenous
dose of Etanercept was well tolerated, suppressed circulating
levels of biologically active TNF alpha between 70% and 85%
for at least 14 days and improved functional status and quality
of life (99). More recently, 47 patients with New York Heart
Association (NYHA) class III–IV heart failure symptoms were
randomized to receive either biweekly subcutaneous Etaner-
cept or placebo for three months. Etanercept effected dose-
related trends in improvements in NYHA classification and
quality of life and decreased cytokine expression (100). How-
ever, to assess the long-term effects of Etanercept, a random-
ized, double-blind and placebo-controlled clinical trial,
RENAISSANCE, is presently enrolling patients with NYHA
class II–IV heart failure symptoms in the U.S., and a compan-
ion study is underway in Europe and Australia.
Conclusions. In summary, both basic and clinical studies
strongly support the hypothesis that myocardial expression
of TNF alpha is an important step in the pathophysiologic
pathway leading to progressive cardiac dilatation and failure.
However, important questions remain to be answered: 1)
What is the signal responsible for activating cardiac
TNF alpha expression? 2) Why does the heart express TNF
alpha? 3) Can we selectively attenuate cardiac TNF alpha
expression? 4) What are the clinical benefits of TNF alpha
inhibition? 5) When during the transition from compen-
sated to decompensated heart failure is TNF alpha ex-
pressed? 6) What role is played by other proinflammatory
cytokines such as IL-1beta? By addressing these important
questions, it is hoped that investigators will be able to better
understand the pathobiology of CHF while at the same
time develop new and exciting therapeutic strategies.
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